Equities research analysts forecast that Clearside Biomedical Inc (NASDAQ:CLSD) will report sales of $50,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Clearside Biomedical’s earnings. The company is scheduled to report its next quarterly earnings report on Thursday, November 14th.
On average, analysts expect that Clearside Biomedical will report full-year sales of $150,000.00 for the current year, with estimates ranging from $90,000.00 to $180,000.00. For the next fiscal year, analysts anticipate that the company will post sales of $10.27 million, with estimates ranging from $540,000.00 to $20.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Clearside Biomedical.
Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.22. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.05 million.
Several equities analysts have recently issued reports on CLSD shares. Wedbush restated a “buy” rating and set a $3.00 target price on shares of Clearside Biomedical in a research report on Monday. Zacks Investment Research downgraded shares of Clearside Biomedical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 8th. Needham & Company LLC lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Friday, August 9th. Laidlaw downgraded shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. Finally, ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $3.50.
Hedge funds have recently added to or reduced their stakes in the business. A.R.T. Advisors LLC acquired a new stake in Clearside Biomedical in the 2nd quarter valued at about $95,000. Jane Street Group LLC purchased a new position in shares of Clearside Biomedical in the second quarter valued at $98,000. Paloma Partners Management Co purchased a new position in shares of Clearside Biomedical in the second quarter valued at $122,000. Finally, Vanguard Group Inc. boosted its stake in shares of Clearside Biomedical by 66.9% in the second quarter. Vanguard Group Inc. now owns 924,485 shares of the company’s stock valued at $899,000 after purchasing an additional 370,690 shares during the period. Institutional investors own 11.95% of the company’s stock.
Shares of Clearside Biomedical stock traded up $0.01 during trading on Friday, hitting $0.84. 75,439 shares of the company were exchanged, compared to its average volume of 413,038. The firm has a market capitalization of $29.44 million, a P/E ratio of -0.31 and a beta of -0.57. Clearside Biomedical has a 1-year low of $0.56 and a 1-year high of $6.27. The firm’s fifty day moving average price is $0.71 and its 200 day moving average price is $1.04. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.47 and a quick ratio of 3.47.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.